Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study

We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14-104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years ( < 0.001) and need for hospitalization ( < 0.001) correlated with higher antibody titers, while asymptomatic status ( < 0.001) and testing >60 days after symptom onset ( = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.

Citing Articles

A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.

Sharun K, Tiwari R, Yatoo M, Natesan S, Megawati D, Singh K Narra J. 2024; 2(3):e92.

PMID: 38449903 PMC: 10914132. DOI: 10.52225/narra.v2i3.92.

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study.

Zirou C, Gumeni S, Bellos I, Ntanasis-Stathopoulos I, Sklirou A, Bagratuni T Viruses. 2023; 15(11).

PMID: 38005927 PMC: 10674840. DOI: 10.3390/v15112250.

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.

Amellal H, Assaid N, Charoute H, Akarid K, Maaroufi A, Ezzikouri S PLoS One. 2023; 18(7):e0288557.

PMID: 37437051 PMC: 10337929. DOI: 10.1371/journal.pone.0288557.

Cystatin-c May Indicate Subclinical Renal Involvement, While Orosomucoid Is Associated with Fatigue in Patients with Long-COVID Syndrome.

Zavori L, Molnar T, Varnai R, Kanizsai A, Nagy L, Vadkerti B J Pers Med. 2023; 13(2).

PMID: 36836605 PMC: 9958557. DOI: 10.3390/jpm13020371.

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination.

Rosati M, Terpos E, Bear J, Burns R, Devasundaram S, Ntanasis-Stathopoulos I Cancers (Basel). 2022; 14(23).

PMID: 36497296 PMC: 9737406. DOI: 10.3390/cancers14235816.

References

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

Schmidt F, Weisblum Y, Muecksch F, Hoffmann H, Michailidis E, Lorenzi J . Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020; 217(11). PMC: 7372514. DOI: 10.1084/jem.20201181. View

Terpos E, Mentis A, Dimopoulos M . Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020; 383(17):1695. DOI: 10.1056/NEJMc2027051. View

Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki S, Ishihara T . Natural History of Asymptomatic SARS-CoV-2 Infection. N Engl J Med. 2020; 383(9):885-886. PMC: 7304419. DOI: 10.1056/NEJMc2013020. View

Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C . Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020; 180(10):1356-1362. PMC: 9377417. DOI: 10.1001/jamainternmed.2020.4616. View

Baig A, Khaleeq A, Ali U, Syeda H . Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020; 11(7):995-998. DOI: 10.1021/acschemneuro.0c00122. View

Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y . Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct Target Ther. 2020; 5(1):180. PMC: 7464057. DOI: 10.1038/s41392-020-00301-9. View

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View

10.

Siracusano G, Pastori C, Lopalco L . Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020; 11:1049. PMC: 7242756. DOI: 10.3389/fimmu.2020.01049. View

11.

Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E . Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020; 20(4):493-506. PMC: 7383117. DOI: 10.1007/s10238-020-00648-x. View

12.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

13.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

14.

Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J . Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clin Infect Dis. 2020; 71(10):2688-2694. PMC: 7314147. DOI: 10.1093/cid/ciaa721. View

15.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

16.

Payne D, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M . Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis. 2016; 22(10):1824-6. PMC: 5038413. DOI: 10.3201/eid2210.160706. View

17.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

18.

Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

19.

Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E . Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018; 10(1):59. PMC: 6063007. DOI: 10.1186/s13073-018-0568-8. View

20.

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis T, Politou M . Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7):834-847. PMC: 7262337. DOI: 10.1002/ajh.25829. View